2.32
0.87%
+0.02
After Hours:
2.32
Immuron Limited ADR stock is currently priced at $2.32, with a 24-hour trading volume of 695.
It has seen a +0.87% increased in the last 24 hours and a -3.73% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.29 pivot point. If it approaches the $2.33 resistance level, significant changes may occur.
Previous Close:
$2.30
Open:
$2.31
24h Volume:
695
Market Cap:
$13.21M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-5.2775
EPS:
-0.4396
Net Cash Flow:
-
1W Performance:
-2.52%
1M Performance:
-3.73%
6M Performance:
+27.47%
1Y Performance:
+1.31%
Immuron Limited ADR Stock (IMRN) Company Profile
Name
Immuron Limited ADR
Sector
Industry
Phone
61 3 9824 5254
Address
62 Lygon Street, Level 3, Carlton, VIC
Immuron Limited ADR Stock (IMRN) Latest News
Immuron Limited to Present at the Emerging Growth Conference
GlobeNewswire Inc.
Immuron Director Resignation
GlobeNewswire Inc.
Immuron to host Live Virtual Event
GlobeNewswire Inc.
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga
Immuron Travelan® sales continued strong growth
GlobeNewswire Inc.
Immuron Limited ADR Stock (IMRN) Financials Data
Immuron Limited ADR (IMRN) Revenue 2024
IMRN reported a revenue (TTM) of $2.35 million for the quarter ending December 31, 2023, a +787.24% rise year-over-year.
Immuron Limited ADR (IMRN) Net Income 2024
IMRN net income (TTM) was -$2.56 million for the quarter ending December 31, 2023, a +23.78% increase year-over-year.
Immuron Limited ADR (IMRN) Earnings per Share 2024
IMRN earnings per share (TTM) was -$0.4481 for the quarter ending December 31, 2023, a +25.24% growth year-over-year.
About Immuron Limited ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Cap:
|
Volume (24h):